BRIEF-Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation

Reuters
28 Apr
BRIEF-Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation

April 28 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O:

  • GALMED SIGNED TERM SHEET FOR THE DEVELOPMENT OF NOVEL SEMAGLUTIDE SUBLINGUAL FORMULATION

  • GALMED PHARMACEUTICALS LTD - NEW FORMULATION OFFERS NON-INVASIVE ALTERNATIVE TO INJECTABLE SEMAGLUTIDE

Source text: ID:nPn2hhnT5a

Further company coverage: GLMD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10